Overview

Location [1]
9q21.33
Pathways
Receptor tyrosine kinase/growth factor signaling, Kinase fusions
Protein [2]
BDNF/NT-3 growth factors receptor
Synonyms [1]
OBHD, GP145-TrkB, TRKB, trk-B, EIEE58

Neurotrophic tyrosine kinase, receptor, type 2 (NTRK2) is a gene that encodes a protein in the neurotrophic tyrosine receptor kinase (NTRK) family that participates in the MAP kinase signaling pathway. Fusions, missense, nonsense, and silent mutations are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.

NTRK2 is altered in 1.27% of all cancers with lung adenocarcinoma, colon adenocarcinoma, cutaneous melanoma, endometrial endometrioid adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].

NTRK2 GENIE Cases - Top Diseases

The most common alterations in NTRK2 are NTRK2 Mutation (1.39%), NTRK2 Amplification (0.04%), NTRK2 Loss (0.03%), NTRK2 A662T (0.02%), and NTRK2 V606I (0.02%) [3].

NTRK2 GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of NTRK2 in Diseases

Malignant Solid Tumor +

Non-Small Cell Lung Carcinoma +

Congenital Mesoblastic Nephroma +

Infantile Fibrosarcoma +

Colorectal Carcinoma +

Non-Hodgkin Lymphoma +

Lymphoma +

Anaplastic Large Cell Lymphoma +

Melanoma +

Malignant Central Nervous System Neoplasm +

Breast Carcinoma +

Acute Leukemia +

Head And Neck Squamous Cell Carcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Multiple Myeloma +

Secretory Breast Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.